← All trials
NCT05415397
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Jun 13, 2022
- Last posted
- Sep 29, 2022
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Free University of AmsterdamLead sponsor
- Free University of AmsterdamOverall official - principal investigator
- Free University of AmsterdamReponsible party - principal investigator
- Netherlands Brain FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.